The global health community has once again found itself in a familiar position: fighting the U.S. on a policy previously seen as a no-brainer. The fight against tuberculosis, the world’s top infectious killer, has been consuming United Nations negotiators for the last two months as they prepare for the first U.N.
Six out of top 10 brands of paracetamol in India – Calpol, Sumo L, P-250, Crocin, Tamin and Fepanil – have registered a fall in annual sales growth in value terms in 2017-18. However, their annual sales in unit terms have comparatively increased in the same period, indicating a price reduction across brands.
Updated 11:16 EDT: This story now includes information about the Food and Drug Administration’s release of a list of complaints against brand-name drugmakers for hindering access to samples for generic testing. When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month’s supply.
The Drug Price Competition and Patent Term Restoration Act – better known as Hatch-Waxman – was signed into law by President Ronald Reagan 34 years ago. Sponsored by Senator Orrin Hatch of Utah, a devout conservative, and Representative Henry Waxman of California, a flaming liberal, its primary purpose was to make drugs more affordable by kick-starting the relatively new generic drug industry.
One of my greatest priorities is to reduce the price of prescription drugs. A BURDEN ON THE AMERICAN PEOPLE: Drug prices are being driven up unfairly, taking a toll on the American people. Excessively high drug prices, foreign freeloading, and a system rigged to reward list price increases, are burdening the American people.
A recent Supreme Court decision on patents – Oil States v. Greene’s Energy Group marks an understated victory, with far-reaching consequences that will positively impact families and communities across America. This case has deep implications for basic economic fairness, with the judiciary recognizing the importance of keeping critical checks in systems that have become far too imbalanced.
Why does it matter what medicines cost? If you are lucky enough to live in a country with comprehensive state-funded healthcare, such as the UK, you probably have no idea how much medicines really cost. But it can be a lot. Some drugs that have been around for ages are very cheap – aspirin, for instance, costs pence.
New Delhi, Mar 4 () National drug pricing regulator NPPA has said medical devices makers and importers are being given the last opportunity to submit data regarding price movement of 19 medical devices notified as drugs by March 15, 2018.
The pharmaceutical industry has suggested to the central government that it should increase its reviewing powers on the decisions taken by National Pharmaceutical Pricing Authority (NPPA). The regulator is learnt to have responded with a contrarian view that the government should “abandon its archaic practice of reviewing NPPA orders” and, instead, establish an independent appellate tribunal.
Some hospitals in the National Capital Region (NCR) prescribed branded medicines that were outside the regulator’s purview and inflated their prices several times in order to boost profit, the National Pharmaceutical Pricing Authority said. Four hospitals in the NCR marked up the retail prices of such medicines as much as 12-fold from the rates at which they were purchased, NPPA said in a report.
NPPA analysis: Three private hospitals earn huge margins on drugs | The Indian Express National Pharmaceutical Pricing Authority (NPPA) on Tuesday came out with a price analysis of three unnamed private hospitals in the city that showed huge margins on MRPs kept by these hospitals on drugs and consumables, ranging from 2112 per cent to 116 per cent.
The National Pharmaceutical Pricing Authority on Monday revised the price of drug eluting stents (DES) downwards by about Rs 2,300 to just under Rs 28,000, while marginally raising the cap on bare metal stents from Rs 7,400 to Rs 7,660. These caps are excluding GST.